But quality-of-life findings should be considered alongside DFS benefit, says researcher ...

Clinicians weigh dual immunotherapy vs monotherapy in metastatic NSCLC, comparing CheckMate 227 and POSEIDON efficacy, PD‑L1 subsets, and toxicity. The oncologists examined deveral pivotal trials ...

A novel immunotherapy combination is proving to be both safe and manageable for patients with prostate cancer, according to updated Phase 1 trial data presented at the 2026 ASCO Genitourinary Cancers ...

A newly discovered cancer trick that weakens immunotherapy may be stopped by everyday statins.

Ipilimumab-nivolumab also linked with better survival but more toxicity in small study ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...

Children with food allergy who used omalizumab plus oral immunotherapy vs. omalizumab alone had similar rates of allergen ...

Phase II data suggest fewer GI adverse effects when given a sequence of biologics ...

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...

Fecal microbiota transplants may enhance patients’ response to immunotherapy, but experts caution that the latest data remain proof-of-concept and far from practice-changing.

Trilaciclib protects bone marrow before SCLC chemotherapy, sharply reducing neutropenia, anemia, and thrombocytopenia, improving fatigue and keeping treatment on schedule without weakening tumor kill.